Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer

Visa fullständig post



Permalänk

http://hdl.handle.net/10138/333053

Citation

Eurola , A , Ristimäki , A , Mustonen , H , Nurmi , A-M , Hagström , J , Haglund , C & Seppänen , H 2021 , ' Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer ' , Scientific Reports , vol. 11 , no. 1 , 9896 . https://doi.org/10.1038/s41598-021-89134-2

Titel: Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer
Författare: Eurola, Annika; Ristimäki, Ari; Mustonen, Harri; Nurmi, Anna-Maria; Hagström, Jaana; Haglund, Caj; Seppänen, Hanna
Upphovmannens organisation: CAN-PRO - Translational Cancer Medicine Program
Department of Surgery
Faculty of Medicine
University of Helsinki
Helsinki University Hospital Area
Department of Pathology
HUSLAB
HUS Diagnostic Center
HUS Abdominal Center
Clinicum
Medicum
II kirurgian klinikka
Datum: 2021-05-10
Språk: eng
Sidantal: 11
Tillhör serie: Scientific Reports
ISSN: 2045-2322
DOI: https://doi.org/10.1038/s41598-021-89134-2
Permanenta länken (URI): http://hdl.handle.net/10138/333053
Abstrakt: Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigated whether podocalyxin expression correlates with treatment response or survival in neoadjuvant-treated PDAC. Through immunohistochemistry, we evaluated podocalyxin expression in 88 neoadjuvant and 143 upfront surgery patients using two antibodies. We developed a six-tier grading scheme for neoadjuvant responses evaluating the remaining tumor cells in surgical specimens. Strong podocalyxin immunopositivity associated with poor survival in the patients responding poorly to the neoadjuvant treatment (HR 4.16, 95% CI 1.56-11.01, p=0.004), although neoadjuvant patients exhibited generally low podocalyxin expression (p=0.017). Strong podocalyxin expression associated with perineural invasion (p=0.003) and lack of radiation (p=0.036). Two patients exhibited a complete neoadjuvant response, while a strong neoadjuvant response (
Subject: HUMAN PROTEIN ATLAS
POOR-PROGNOSIS
DUCTAL ADENOCARCINOMA
MAJOR SIALOPROTEIN
EXPRESSION
SURVIVAL
CHEMORADIOTHERAPY
CHEMORADIATION
GEMCITABINE
VALIDATION
3122 Cancers
Referentgranskad: Ja
Licens: cc_by
Användningsbegränsning: openAccess
Parallelpublicerad version: publishedVersion


Filer under denna titel

Totalt antal nerladdningar: Laddar...

Filer Storlek Format Granska
s41598_021_89134_2.pdf 1.314Mb PDF Granska/Öppna

Detta dokument registreras i samling:

Visa fullständig post